Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | GLRA3 | O75311 | 1/20 | 0.33 |
| ▸ | GLRB | P48167 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9063420 | 0.85 | GLRA3 (0.37) | KMT2AGLRA3GLRB | |
| SCHEMBL11175160 | 0.85 | GLRA3 (0.37) | KMT2AGLRA3GLRB | |
| SCHEMBL9588924 | 0.83 | GLRA3 (0.31) | GLRA3GLRB | |
| SCHEMBL7512887 | 0.72 | NR5A2 (0.33) | GLRA3GLRB | |
| SCHEMBL1264011 | 0.71 | TSHR (0.64) | TSHRKMT2AALDH1A1ESR1HSD17B10 | |
| SCHEMBL9737841 | 0.70 | TSHR (0.46) | TSHRKMT2AALDH1A1ESR1HSD17B10 | |
| SCHEMBL9736787 | 0.69 | TSHR (0.45) | TSHRKMT2AALDH1A1ESR1HSD17B10 | |
| SCHEMBL9742368 | 0.67 | TSHR (0.63) | TSHRKMT2AALDH1A1ESR1HSD17B10 | |
| SCHEMBL9461311 | 0.67 | GAA (0.31) | — | |
| SCHEMBL27716443 | 0.67 | GLRA3 (0.55) | KMT2AGLRA3GLRBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5112890-A | Piperidine compound with oxygen bonded to ring nitrogen | CIBA-GEIGY CORPORATION (US) | 1992-05-12 | — | — | US | claimed |
| US-8163934-B2 | Ultraviolet light absorbing ketones of 2-(2-hydroxyphenyl) benzotriazole | CHANG CHIA-HU (US) | 2012-04-24 | — | — | US | disclosed |
| EP-2332013-A1 | ULTRAVIOLET LIGHT ABSORBING KETONES OF 2-(2-HYDROXYPHENYL) BENZOTRIAZOLE | Chang, Chia-Hu (US) | 2011-06-15 | — | — | EP | disclosed |
| US-20110038816-A1 | Ultraviolet light absorbing ketones of 2-(2-hydroxyhenyl) benzotriazole | CHANG CHIA-HU | 2011-02-17 | — | — | US | disclosed |
| US-7847103-B2 | Ultraviolet light absorbing ketones of 2-(2-hydroxyphenyl) benzotriazole | CHANG CHIA-HU | 2010-12-07 | — | — | US | disclosed |
| US-20100086500-A1 | Ultraviolet light absorbing ketones of 2-(2-Hydroxyphenyl) benzotriazole | CHANG CHIA-HU | 2010-04-08 | — | — | US | disclosed |
| WO-2010039229-A1 | ULTRAVIOLET LIGHT ABSORBING KETONES OF 2-(2-HYDROXYPHENYL) BENZOTRIAZOLE | CHANG CHIA-HU (US) | 2010-04-08 | — | — | WO | disclosed |
| EP-0309400-B1 | N-acyloxy hindered amine stabilizers | CIBA GEIGY AG (CH) | 1994-03-02 | — | — | EP | disclosed |
| EP-0309400-A2 | N-acyloxy hindered amine stabilizers | CIBA-GEIGY AG (CH) | 1989-03-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110038816-A1 | Ultraviolet light absorbing ketones of 2-(2-hydroxyhenyl) benzotriazole | HCRTR2, HCRTR1, POLL | TSHR 983/4885KMT2A 345/4885GLRA3 1620/4885 |
| US-20100086500-A1 | Ultraviolet light absorbing ketones of 2-(2-Hydroxyphenyl) benzotriazole | HCRTR2, HCRTR1, PAH | TSHR 996/4885KMT2A 357/4885GLRA3 1512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.